IRWD Overview

Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.

Wall Street analysts forecast IRWD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRWD is6.23 USD with a low forecast of 5.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Ironwood Pharmaceuticals Inc revenue for the last quarter amounts to 47.71M USD, decreased -47.31

Ironwood Pharmaceuticals Inc. EPS for the last quarter amounts to -0.02 USD, decreased -300.00

Ironwood Pharmaceuticals Inc (IRWD) has 100 emplpoyees as of March 11 2026.

Today IRWD has the market capitalization of 603.32M USD.